The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen.
MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to end the week before last (April 9). Having only set its previous all-time best of 110.96 on Feb. 15, the industry’s topsy-turvy run gave no indication of which direction it was heading next.
However, after the rise over the past couple of weeks, the industry rode that wave to a new all-time high of 112.25 to end last week on April 16. That represents a 2.6% rise from the previous week’s tally.
Improvements continue to shine a light on the strong position the industry has settled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 21.6% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 80.1% increase from the mid-pandemic low of 62.13 (March 23, 2020).
The overall markets also rose along with medtech over the past week, albeit in a slightly less drastic way, with the S&P 500 Index growing by 1.4% and the Dow Jones Industrial Average ticking up by 1.2%.
The industry continues to recover from the COVID-19 pandemic and its effects. Here are some of the major highlights from the past week:
- 9 medical devices you should keep an eye out for in 2021
- Siemens Healthineers completes Varian acquisition
- Vicarious Surgical to go public in $1.1B SPAC deal
- Analysts are bullish on Align Technology
- Medical device companies put $3.6 billion in docs’ pockets, study finds
- Medline Industries up for sale?
- Survey shows solid medical device industry performance despite pandemic
- Microsoft spending $19.7B on Nuance and its AI for healthcare providers
- Thermo Fisher to buy PPD for $17B
- Amgen completes $1.9B acquisition of Five Prime Therapeutics
- DiaSorin to buy Luminex for $1.8B
